Premium
Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma
Author(s) -
Daliani Danai D.,
Tannir Nizar M.,
Papandreou Christos N.,
Wang Xuemei,
Swisher Stephen,
Wood Christopher G.,
Swanson David A.,
Logothetis Christopher J.,
Jonasch Eric
Publication year - 2009
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2009.08490.x
Subject(s) - metastasectomy , medicine , systemic therapy , renal cell carcinoma , adjuvant therapy , surgery , prospective cohort study , kidney cancer , disease , metastasis , cancer , chemotherapy , breast cancer
OBJECTIVE To prospectively establish objective selection criteria for metastasectomy in patients with metastatic renal cell carcinoma (mRCC). PATIENTS AND METHODS Between 1991 and 1999, 38 patients with mRCC with responsive or stable disease after initial systemic therapy, and with potentially resectable disease, were enrolled. Patients had a metastasectomy with curative intent and received consolidative adjuvant systemic therapy. RESULTS Of the patients enrolled, 79% had stable disease after initial systemic therapy and 21% had a partial or complete response. Most (84%) had metastasectomy of one organ site. There was surgically no evidence of disease (sNED) in 76%. Operative morbidity and mortality were acceptable and 90% of the patients received adjuvant systemic therapy. The median (95% confidence interval) survival was 4.7 (3.0–7.8) years, and the median time to progression was 1.8 (0.8–3.1) years. Eight of 38 patients (21%) remained free of disease by the end of the study. Significant predictors of outcome were lack of sNED after metastasectomy, and the presence of pulmonary metastases. The median overall survival for those who had sNED was 5.6 years, vs 1.4 years for those who did not ( P < 0.001). CONCLUSIONS Metastasectomy in patients with mRCC not progressing after systemic therapy is feasible, with acceptable morbidity. Predictive factors for long‐term outcome include pulmonary metastases and sNED. Future work evaluating treatments that can convert patients into surgical candidates will increase the cure rate of patients with mRCC.